Intercept Pharma (ICPT) on Watch Following Gilead's Nash Data

October 20, 2016 10:13 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Intercept Pharma (NASDAQ: ICPT) was in focus Thursday after Gilead Sciences (NASDAQ: GILD) reported Top-Line phase 2 results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD).

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Add Your Comment